Lieke Wever
Papers
1
Total Citations
3
H-Index
1
About
Dr. Lieke Wever is a leading oncological researcher whose work centers on the intersection of advanced molecular imaging and prostate cancer prognostication. Her primary contributions lie in refining risk stratification for patients undergoing radical prostatectomy, with a particular focus on the clinical utility of PSMA PET/CT. In her landmark 2025 study, Dr. Wever demonstrated that PSMA PET/CT-based local staging offers superior predictive value for biochemical recurrence-free survival compared to conventional imaging, directly addressing a critical gap in personalized treatment planning. This work, already garnering 3 citations shortly after publication, establishes a new benchmark for integrating molecular imaging into postoperative risk assessment. By systematically evaluating the association between PSMA PET/CT characteristics and oncologic outcomes, Dr. Wever has provided clinicians with a powerful tool to identify high-risk patients earlier, potentially guiding adjuvant therapy decisions. Her research bridges the gap between cutting-edge imaging technology and actionable clinical insights, positioning her as a rising authority in urologic oncology. For students and researchers, Dr. Wever’s work exemplifies how rigorous imaging-based studies can translate into tangible improvements in cancer care.
Research Focus
Key Achievements
Top Papers
- 1